Show
Sort by
-
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
-
- Journal Article
- A1
- open access
Quality of life analyses in patients with multiple myeloma : results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
-
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial
-
- Journal Article
- A1
- open access
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
-
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
-
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
-
Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant : the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial
(2020) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 20(Supplement 1). p.S307-S308 -
Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma : ICARIA-MM high-risk cytogenetics subgroup analysis
-
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma
-
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial